Prognostic Value of Change in Anti-thyroglobulin Antibodies After Thyroidectomy in Patients with Papillary Thyroid Carcinoma

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2017 Oct 27

PMID 29071517

Citations 11

Authors

A Ernaga-Lorea

M C Hernandez-Morhain

E Anda-Apinaniz

J J Pineda-Arribas

I Migueliz-Bermejo

N Eguilaz-Esparza

A Irigaray-Echarri

Affiliations

Soon will be listed here.

Abstract

Purpose: Anti-thyroglobulin antibodies (TgAb) can be used as a surrogate tumor marker in the follow-up of papillary thyroid carcinoma (PTC). We try to determine if the change in TgAb levels in the first post-operative year is a good predictor of persistence/recurrence risk in TgAb-positive PTC patients.

Methods/patients: 105 patients with PTC who underwent thyroidectomy between 1988 and 2014 were enrolled. We calculated the percentage of change in TgAb levels with the first measurement at 1-2 months after surgery and the second one at 12-14 months.

Results: TgAb negativization was observed in 29 patients (27.6%), a decrease of more than 50% was observed in 57 patients (54.3%), less than 50% in 12 patients (11.4%) and in 7 patients (6.7%) the TgAb level had increased. The percentage of persistence/recurrence was 0, 8.8, 16.7 and 71.4% in each group, respectively (p < 0.001). In the multivariate analysis, only the percentage of change in TgAb showed a significant association with the risk of persistence/recurrence, regardless of other factors such as age, size and TNM stages.

Conclusions: Changes in TgAb levels in the first year after surgery can predict the risk of persistence/recurrence of TgAb-positive PTC patients. Patients who achieved negativization of TgAb presented an excellent prognosis.

Citing Articles

Analysis of the prognostic value of thyroglobulin antibody change trends during follow-up after I treatment in patients with differentiated thyroid carcinoma.

Ge H, Chen W, Lin Z, Li Y, Chen S Front Oncol. 2025; 15:1496594.

PMID: 39968066 PMC: 11832372. DOI: 10.3389/fonc.2025.1496594.

Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone.

Matrone A, Faranda A, Torregrossa L, Gambale C, Minaldi E, Prete A Curr Oncol. 2024; 31(9):5528-5536.

PMID: 39330037 PMC: 11431500. DOI: 10.3390/curroncol31090409.

Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.

Zhao Y, Mu Z, Liang D, Zhang T, Zhang X, Sun D Front Endocrinol (Lausanne). 2024; 15:1354426.

PMID: 38721144 PMC: 11076744. DOI: 10.3389/fendo.2024.1354426.

The effect of positive thyroglobulin antibodies on the prognosis and treatment response in patients with papillary thyroid carcinoma.

Sanjari M, Ordooei M, Amirkhosravi L, Naghibzadeh-Tahami A, Nazemi S Heliyon. 2024; 10(4):e26092.

PMID: 38384522 PMC: 10879018. DOI: 10.1016/j.heliyon.2024.e26092.

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.

Han N, Lu C, Li J, Wang C, Zhao Z, Zhang Y Front Endocrinol (Lausanne). 2023; 14:1222470.

PMID: 37810895 PMC: 10556735. DOI: 10.3389/fendo.2023.1222470.

References

Hsieh C, Wang P . Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid. 2013; 24(3):488-93. DOI: 10.1089/thy.2012.0611. View

Phan H, Jager P, van der Wal J, Sluiter W, Plukker J, Dierckx R . The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 2008; 158(1):77-83. DOI: 10.1530/EJE-07-0399. View

Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E . Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid. 2014; 24(7):1139-45. PMC: 4080868. DOI: 10.1089/thy.2013.0698. View

Medeiros-Neto G . Iodine supplementation and thyroid autoimmunity. Clin Endocrinol (Oxf). 1994; 40(3):435. View

Demers L, Spencer C . Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf). 2003; 58(2):138-40. DOI: 10.1046/j.1365-2265.2003.01681.x. View

Spencer C, Petrovic I, Fatemi S, LoPresti J . Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014; 99(12):4589-99. PMC: 4297889. DOI: 10.1210/jc.2014-1203. View

Grebe S . Thyroglobulin autoantibodies, thyroid nodules, and new insights into some old questions. Thyroid. 2010; 20(8):841-2. DOI: 10.1089/thy.2010.1651. View

Tsushima Y, Miyauchi A, Ito Y, Kudo T, Masuoka H, Yabuta T . Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients. Endocr J. 2013; 60(7):871-6. DOI: 10.1507/endocrj.ej12-0410. View

Li C, Yu W, Fan J, Li G, Tao X, Feng Y . Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers. Oncotarget. 2016; 7(31):49930-49938. PMC: 5226558. DOI: 10.18632/oncotarget.10236. View

10.

Kumar A, Shah D, Shrihari U, Dandekar S, Vijayan U, Sharma S . Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994; 4(2):199-202. DOI: 10.1089/thy.1994.4.199. View

11.

Spencer C . Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab. 2004; 89(8):3702-4. DOI: 10.1210/jc.2004-0986. View

12.

Yamada O, Miyauchi A, Ito Y, Nakayama A, Yabuta T, Masuoka H . Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy. Endocr J. 2014; 61(10):961-5. DOI: 10.1507/endocrj.ej14-0275. View

13.

Hollowell J, Staehling N, Flanders W, Hannon W, Gunter E, Spencer C . Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2):489-99. DOI: 10.1210/jcem.87.2.8182. View

14.

Gorges R, Maniecki M, Jentzen W, Sheu S, Mann K, Bockisch A . Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005; 153(1):49-55. DOI: 10.1530/eje.1.01940. View

15.

Qin J, Yu Z, Guan H, Shi L, Liu Y, Zhao N . High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma. Dis Markers. 2015; 2015:648670. PMC: 4639663. DOI: 10.1155/2015/648670. View

16.

Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E . Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh). 1988; 119(3):373-80. DOI: 10.1530/acta.0.1190373. View

17.

Kim T, Kim W, Kim E, Ryu J, Yeo J, Kim S . Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004; 90(3):1440-5. DOI: 10.1210/jc.2004-1771. View

18.

Soyluk O, Boztepe H, Aral F, Alagol F, Ozbey N . Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial.... Thyroid. 2011; 21(12):1301-8. DOI: 10.1089/thy.2011.0122. View

19.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

20.

Spencer C, Takeuchi M, Kazarosyan M, Wang C, Guttler R, Singer P . Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998; 83(4):1121-7. DOI: 10.1210/jcem.83.4.4683. View